SAN DIEGO, Jan. 9, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that it has entered into an exclusive licensing agreement granting Abbott Laboratories Limited a global, diversified healthcare company, the exclusive rights to market Vitaros® (alprostadil), Apricus Bio’s treatment for erectile dysfunction (“ED”), in Canada. “We are optimistic about the potential of the technology, effectiveness and market potential of Vitaros®,” said Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus Bio.
